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An intriguing recent study examines the role of miR-
1202, a glutamate receptor regulating microRNA, in
regulating major depressive disorder.biological elements that segregate by sex and occur atThe challenge of major depressive disorder
Major depressive disorder (MDD), a common, yet debili-
tating and economically costly, psychiatric disorder [1],
has proven surprisingly refractory to molecular-genetic
investigation and the development of biomarkers for
diagnosis and treatment. However, although there was
initial excitement over positive findings in studies of
genetic linkage [2], genome-wide association of single-
nucleotide polymorphisms (SNPs) [3] and copy-number
variants [4], none of these areas of investigation has re-
sulted in replicated findings, and a recent genome-wide
mega-analysis of SNPs was entirely negative [5]. Simi-
larly, no biomarker for MDD has been found to be clin-
ically useful, despite the pressing need in psychiatry for
objective tests for diagnosis and treatment response. The
usual genetic model that is used to explain liability in
complex disorders is one of polygenic heterogeneity [6],
with many variants of small effect co-acting to produce
a liability to psychiatric disorders that develops over the
lifetime in interplay with the environment. Such a model
was first postulated for common psychiatric disorders
nearly a half-century ago [7] and has proved to be en-
during. However, it remains a general theory that is ‘ag-
nostic’ about what the component polygenes might be.
In search of further specific elements of the genome
that could help explain the heritability of common psy-
chiatric disorders, the role of microRNAs (miRNAs) has
recently been investigated. Within mammals, it is esti-
mated that 60% of all protein-coding genes are regulated
by miRNAs, contributing widely to the regulation of
most cellular biochemical processes [8]. In addition,
miRNAs are found in plasma and might be useful as* Correspondence: james.rucker@kcl.ac.uk
MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, The
Institute of Psychiatry, Kings College London, 16 De Crespigny Park, London
SE5 8AF, UK
© 2014 Rucker and McGuffin; licensee BioMed
medium, for 12 months following its publicat
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.biomarkers [9] - thus, they are particularly relevant can-
didates for study in psychiatric disorders. MDD tends to
develop after the onset of puberty, with a peak in inci-
dence during early adult life, and a particular preponder-
ance for the female sex. This might suggest regulatory
specific points in time during development.
Recently, Lopez and colleagues have published a
thought-provoking article in Nature Medicine that impli-
cates a particular miRNA in the development of MDD
[10]. The study provides evidence from a number of dif-
ferent experimental paradigms that miR-1202 exists in a
dose-dependent relationship with expression of the gene
GRM4 (encoding metabotropic glutamate receptor 4) in
the human prefrontal cortex and that the expression of
miR-1202 is related to successful antidepressant
treatment.miR-1202 is differentially expressed in patients
with depression
The authors initially investigated differences in miRNA
expression in the prefrontal cortices of deceased individ-
uals with diagnoses of MDD compared with deceased,
psychiatrically healthy control samples. The levels of
miR-1202 expression were significantly decreased in
brains from depressed individuals when compared with
those of controls. Psychiatric diagnosis was made post-
mortem, based on medical records. An in silico investi-
gation of evolutionary conservation of miR-1202 across
the genomes of 100 animal species revealed that miR-
1202 is present only in humans and primates. To con-
firm this finding experimentally, Lopez and colleagues
measured expression in the brains of six representative
animal species: human, cynomolgus monkey (Macaca
fasciculari), rhesus monkey (Macaca mulatta), rat (Rat-
tus norvegicus), mouse (Mus musculus) and chicken
(Gallus gallus) [10]. The authors showed that miR-1202
was not found in rat, mouse and chicken brain but was
found in primate brains, with the highest levels in hu-
man brain, which also had higher levels than in 10 other
investigated forms of human tissue. To predict the func-
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potential gene targets, cross-referencing these with genes
expressed and upregulated in the prefrontal cortices
of subjects with depression. Of five potential genes,
miR-1202 was found to correlate negatively only with
expression of GRM4, encoding subtype four of the me-
tabotropic glutamate receptor. In a replication analysis,
the authors measured the expression of miR-1202 and
GRM4 in an independent sample of human prefrontal
cortices that also included depressed individuals who
were taking antidepressants at the time of death. Repli-
cating their original findings, the authors also noted that
miR-1202 levels were no different between controls and
depressed individuals taking antidepressants, suggesting
that not only are the levels of miR-1202 inversely related
to the level of GRM4 expression, but also that antide-




To investigate this modulatory effect further, human em-
bryonic kidney (HEK) cells were used to perform func-
tional experiments investigating the interaction between
miR-1202, GRM4 expression and antidepressants. HEK
cells were used because they particularly express GRM4
without expressing miR-1202. Treatment of HEK cells
with a miR-1202 mimic resulted in a decreased expres-
sion of GRM4, and co-treatment with the miR-1202
mimic together with an agent that interfered with the
predicted binding sites of miR-1202 to the transcribed
GRM4 mRNA resulted in GRM4 expression levels
returning to baseline. Further investigation of the rela-
tionship between miR-1202 and GRM4 with agonists
and antagonists of GRM4 in neural progenitor cells
(NPCs) suggested that miR-1202 exists in a bidirectional
relationship with GRM4 expression. To investigate the
effects of antidepressants on this relationship, the au-
thors treated NPCs (which show a serotonergic profile)
with the archetypal tricyclic antidepressant imipramine,
the selective serotonin reuptake inhibitor (SSRI) anti-
depressant citalopram or a control possessing no active
drug. Although there was no effect of acute (24 hours)
treatment with either drug on miR-1202 levels or GRM4
expression, chronic treatment (15 days) with either drug
resulted in an up-regulation of miR-1202 - findings that
were also confirmed using immunohistochemistry. Of
note, this effect was not observed when treating cells
with the drugs valproate or lithium, neither of which has
a direct effect on the sodium-dependent serotonin trans-
porter (SERT). Knockdown experiments showed that the
increase in miR-1202 concentrations is dependent on
SERT and the reuptake blockade elicited by conventional
antidepressants. To rule out global miRNA dysregulationas an explanation of the observed effects, the authors
additionally measured the expression levels of miRNAs
known to be ubiquitously expressed, but found no
differences in expression after chronic antidepressant
treatment.
To confirm these findings in vivo, the authors mea-
sured blood levels of miR-1202 in treatment-naïve pa-
tients with MDD and healthy controls. The levels of
mir-1202 were found to be decreased in patients with
depression. Patients were then treated with citalopram
for eight weeks and classified as responders or non-
responders on the basis of relative changes in Hamilton
Depression (HAM-D) rating-scale scores. Although
those who achieved remission from symptoms as speci-
fied by the HAM-D score showed increased miR-1202
levels after eight weeks of treatment with citalopram,
there was no difference in expression in miR-1202 levels
between non-responders and psychiatrically healthy con-
trols without major depressive disorder. The change in
depression severity, as defined by HAM-D scores, was
negatively correlated with miR-1202 expression levels.Concluding remarks
This paper presents a striking investigative narrative,
providing evidence from a number of different angles
that a specific miRNA is a biologically plausible bio-
marker for detection of, and treatment response in,
MDD and is potentially of considerable interest to the
relevant research and clinical communities. However, it
is sensible to urge caution in such circumstances. It
would indeed be a remarkable finding if such a clinically
and biologically heterogeneous disorder as MDD was re-
ducible, even in part, to a single biological entity, and
one might have expected indications towards this previ-
ously. The glutamate system is the major excitatory
neurotransmitter in the brain, and it would be unsur-
prising to find biological links to MDD within it, but
certainly surprising to find that molecular regulation of
a particular subtype of glutamate receptor was associ-
ated with something as conceptually distant as the
HAM-D score, a clinically applied measure of subject-
ively experienced symptoms and observable clinical signs
in MDD. Genetic investigation into MDD has failed to
explain why significant heritability figures are obtained
in twin studies, but a tagging SNP would be expected to
achieve genome-wide levels of statistical significance in
mega-analyses of MDD [5] if any particular genetic or
epigenetic explanation contributed very significantly to
the disorder - although there are likely also to be excep-
tions to this observation. Overall, these provocative and
interesting results will certainly require independent rep-
lication - however, they present a potentially novel and
intriguing facet of the complex genetics of MDD.
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